0.00Open0.00Pre Close0 Volume0 Open Interest3.50Strike Price0.00Turnover1102.00%IV-13.27%PremiumJan 17, 2025Expiry Date0.41Intrinsic Value100Multiplier12DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.1705Delta0.0405Gamma1.25Leverage Ratio-0.0668Theta-0.0008Rho-0.21Eff Leverage0.0014Vega
Revance Therapeutics Stock Discussion
Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement
Crown Laboratories and Revance Therapeutics (NASDAQ: RVNC) have announced an amended merger agreement where Crown will acquire all outstanding Revance shares for $3.10 per share in cash through a tender offer. The amendment comes after several developments, including Revance's settlement with Teoxane regarding distribution agreements and revised brand guidelines, which are expect...
📊⚡️📊
No comment yet